All lobbying filings

THE NICKLES GROUP, LLC

Lobbying for EMERGENT BIOSOLUTIONS · Pharmaceutical company.

Filing 3rd Quarter - Report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 20, 2025

Income

$40,000.00

What the client paid this registrant for the period.

Client based in

Maryland

Official filing document

Government bodies contacted 3

HOUSE OF REPRESENTATIVES
Office of Management & Budget (OMB)
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Lobbying activity 3

Budget/Appropriations

Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY2026. Opioid and heroin addiction legislation, naloxone access and awareness.

Health Issues

Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act, Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY2026, Opioid crisis legislation, naloxone access and awareness, FY2026 NDAA provisions related to biological and chemical defense and access to naloxone.

Defense

National Defense Authorization Act for FY2026, provisions related to biological and chemical defense and access to naloxone.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.